Movement Alert｜Akeso Bio Falls 3.04% in Regular Trading, Post-ASCO Selling Pressure Resumes After Brief Buyback-Driven Rebound

Market Focus06-15

On June 15, Akeso Bio (09926.HK) fell 3.04% in regular trading, trading at HK$89.3/share, with turnover of HK$1.363 billion.

The decline follows the company's board approval of a share repurchase plan of up to HK$200 million, which had briefly lifted sentiment. However, sustained profit-taking by event-driven funds after the ASCO catalyst has resumed dominance over price action. The company's core product ivonescimab (AK112) delivered positive OS results from the HARMONi-6 study at the ASCO plenary session on June 1, but the stock has since declined significantly as institutional investors locked in gains post-data release.

Compounding the pressure, reports of potential US restrictions on investment in China's biotech sector and broader market concerns over innovative drug profitability continue to weigh on sentiment. Despite multiple brokerages including Zhongtai Securities maintaining buy ratings and highlighting the company's path to profitability inflection, fund-flow selling pressure continues to dominate short-term trading dynamics.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1109054535?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-15 14:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1109054535","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Akeso Bio Falls 3.04% in Regular Trading, Post-ASCO Selling Pressure Resumes After Brief Buyback-Driven Rebound","media":"Market Focus","content":"<p><p>On June 15, Akeso Bio (09926.HK) fell 3.04% in regular trading, trading at HK$89.3/share, with turnover of HK$1.363 billion.</p><p>The decline follows the company's board approval of a share repurchase plan of up to HK$200 million, which had briefly lifted sentiment. However, sustained profit-taking by event-driven funds after the ASCO catalyst has resumed dominance over price action. The company's core product ivonescimab (AK112) delivered positive OS results from the HARMONi-6 study at the ASCO plenary session on June 1, but the stock has since declined significantly as institutional investors locked in gains post-data release.</p><p>Compounding the pressure, reports of potential US restrictions on investment in China's biotech sector and broader market concerns over innovative drug profitability continue to weigh on sentiment. Despite multiple brokerages including Zhongtai Securities maintaining buy ratings and highlighting the company's path to profitability inflection, fund-flow selling pressure continues to dominate short-term trading dynamics.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Akeso Bio Falls 3.04% in Regular Trading, Post-ASCO Selling Pressure Resumes After Brief Buyback-Driven Rebound</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Akeso Bio Falls 3.04% in Regular Trading, Post-ASCO Selling Pressure Resumes After Brief Buyback-Driven Rebound\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-15 14:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 15, Akeso Bio (09926.HK) fell 3.04% in regular trading, trading at HK$89.3/share, with turnover of HK$1.363 billion.</p><p>The decline follows the company's board approval of a share repurchase plan of up to HK$200 million, which had briefly lifted sentiment. However, sustained profit-taking by event-driven funds after the ASCO catalyst has resumed dominance over price action. The company's core product ivonescimab (AK112) delivered positive OS results from the HARMONi-6 study at the ASCO plenary session on June 1, but the stock has since declined significantly as institutional investors locked in gains post-data release.</p><p>Compounding the pressure, reports of potential US restrictions on investment in China's biotech sector and broader market concerns over innovative drug profitability continue to weigh on sentiment. Despite multiple brokerages including Zhongtai Securities maintaining buy ratings and highlighting the company's path to profitability inflection, fund-flow selling pressure continues to dominate short-term trading dynamics.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09926","symbol_name":"康方生物","start_time":0,"source_url":"","article_id":"1109054535","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1109054535","pubTimestamp":1781504608,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 15, Akeso Bio (09926.HK) fell 3.04% in regular trading, trading at HK$89.3/share, with turnover of HK$1.363 billion.The decline follows the company's board approval of a share repurchase plan...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09926":"康方生物"},"translate_title":"动向提示|康方生物常规交易跌3.04%，ASCO后抛压在短暂回购驱动反弹后恢复","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09926":1},"content_text":"On June 15, Akeso Bio (09926.HK) fell 3.04% in regular trading, trading at HK$89.3/share, with turnover of HK$1.363 billion.The decline follows the company's board approval of a share repurchase plan of up to HK$200 million, which had briefly lifted sentiment. However, sustained profit-taking by event-driven funds after the ASCO catalyst has resumed dominance over price action. The company's core product ivonescimab (AK112) delivered positive OS results from the HARMONi-6 study at the ASCO plenary session on June 1, but the stock has since declined significantly as institutional investors locked in gains post-data release.Compounding the pressure, reports of potential US restrictions on investment in China's biotech sector and broader market concerns over innovative drug profitability continue to weigh on sentiment. Despite multiple brokerages including Zhongtai Securities maintaining buy ratings and highlighting the company's path to profitability inflection, fund-flow selling pressure continues to dominate short-term trading dynamics.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1109054535","isCrawlerRequest":true}